Topic resource collection
Approved comparison material connected to this topic.
75 resourcesRead both sides
NR (Nicotinamide Riboside) Converted to NMN, then to NAD+ Well-researched, oral bioavailability, generally well-tolerated Requires enzymatic conversion, individual response may vary NMN (Nicotinamide Mononucleotide) Direct precur…
Let's break down the most common p21 storage conditions and their general implications. This table offers a quick reference for making informed decisions in your lab, especially when considering the long-term viability of your va…
Kisspeptin Analogs GnRH pulse frequency modulation 20–35% increase in intact HPG axis subjects (2025 Mayo Clinic trial) Daily or alternate-day subcutaneous Yes. Late evening or early morning aligned with natural GnRH peaks Most d…
Osteoporosis peptides work through two distinct biological pathways: anabolic stimulation and antiresorptive inhibition. PTH 1-34 (teriparatide) and PTHrP analogs (abaloparatide) activate the parathyroid hormone receptor on osteo…
PD-1/PD-L1 Mimetics Checkpoint inhibition. Blocks T-cell exhaustion signaling Melanoma, triple-negative breast cancer, non-small cell lung cancer 8–14 hours (D-amino acid substitution + PEGylation) 18–35% ORR depending on tumor t…
| Peptide Class | Mechanism | NASH Resolution Rate (%) | Fibrosis Improvement (%) | Mean Weight Loss (%) | Primary Limitation | Professional Assessment ||—|—|—|—|—|—|| Triple-Agonist (GLP-1/GIP/Glucagon) | Activates three metabol…
| Peptide | Mechanism | BMD Increase (Lumbar Spine, 18mo) | Fracture Risk Reduction | Dosing Frequency | FDA Status 2026 | Professional Assessment ||—|—|—|—|—|—|| Teriparatide (PTH 1-34) | PTH receptor agonist. Stimulates osteobl…
Kisspeptin-54 Triggers GnRH pulse → LH surge for ovulation IVF ovulation trigger (replaces hCG in high responders) 80% reduction (0.8% vs 4.2% with hCG) Phase 3 complete, FDA Fast Track designation Gold standard for OHSS preventi…
| Peptide Class | Lead Compound | Mechanism | Phase | Primary Endpoint | Completion Date | Key Findings (2026 Data) ||—|—|—|—|—|—|| Thymosin Beta-4 Derivatives | Tβ4 1-4 topical cream | Filaggrin upregulation, ceramide synthesis …
BPC-157 NMDA modulation, VEGF upregulation, substance P reduction Neuropathic (post-herpetic neuralgia, diabetic neuropathy, CIPN) Intranasal 250–500mcg daily OR subcutaneous 250–500mcg twice daily Phase II trials. Moderate evide…
Single-Pathway NF-kB Inhibitors Blocks IKK enzyme activation None 18–24% biomarker reduction 8% (GI upset, injection site reaction) Effective but limited durability. Inflammatory rebound occurs 4–6 weeks post-discontinuation in 4…
Growth hormone secretagogues don't directly activate mTOR (mechanistic target of rapamycin), the primary signaling pathway for muscle protein synthesis. This is the critical mechanistic difference between peptides and anabolic st…
Purity Verification Self-reported "≥95%" Batch-specific HPLC (97.2–99.1%) Generic certificates, no batch traceability Post-2026 compliance eliminates the 5–10% margin of error that invalidated concentration-dependent research Man…
DSIP GABA-A receptor agonism in VLPO Strong (Phase 2/3 trials, polysomnography validation) 90 minutes pre-sleep, subcutaneous Minimal. Transient injection site redness Most clinically validated for extending slow-wave sleep; timi…
The table below compares the three most-studied immune peptides as of 2026 based on mechanism, clinical trial status, and documented biomarker changes. Thymalin Thymic peptide fraction. Stimulates thymopoiesis and naive T-cell pr…
This table compares the primary libido-enhancing peptides with meaningful research updates in 2026, focusing on mechanism, updated dosing ranges, and clinical considerations identified this year. PT-141 (Bremelanotide) MC3R/MC4R …
Before selecting a peptide protocol, understand how mechanisms differ: DSIP GABA-A receptor modulation in VLPO Sleep onset latency (−18 min), slow-wave duration (+22%) Neutral to positive 7–14 days Best first-line option for slee…
Exogenous testosterone. Whether cypionate, enanthate, or undecanoate esters. Suppresses endogenous production through negative feedback inhibition. When synthetic testosterone binds to androgen receptors in the hypothalamus and p…
Ipamorelin GHSR1a agonist (ghrelin mimetic). Stimulates pulsatile GH release without cortisol/prolactin spike 200–300mcg subcutaneous 3× weekly, 60–90min pre-training ~2 hours 2.8–3.2kg (with resistance training) Injection site r…
| Peptide Class | Primary Mechanism | Molecular Weight | Documented Dermal Penetration | Clinical Efficacy (MASI Reduction) | Stability pH Range | Typical Adverse Events ||—|—|—|—|—|—|| α-MSH Receptor Antagonists (ASIP analogs) |…